论文部分内容阅读
用放射免疫分析法（ＲＩＡ）检测了１０９例肺癌患者（腺癌３５例、鳞癌３２例、小细胞癌４２例）及对照组３０例的血清ＣＥＡ、ＳＦ、β２－ＭＧ含量，并对２０例肺癌患者化疗前、后的含量变化进行比较。结果表明，肺癌组血清ＣＥＡ、ＳＦ、β２－ＭＧ含量显著高于对照组（Ｐ＜０．０１），其单检阳性率依次为５６．９％、７２．５％、４７．７％，而ＣＥＡ、ＳＦ、β２－ＭＧ联检阳性率可达９１．７％。化疗后肺癌患者β２－ＭＧ含量与化疗前自身对照无明显下降（Ｐ＞０．０５），而ＣＥＡ与ＳＦ则明显下降（Ｐ＜０．０１）。由此说明，上述三项指标联检对肺癌诊治具有重要的临床价值。
Radioimmunoassay (RIA) was used to detect serum CEA, SF, and β2-MG levels in 109 patients with lung cancer (adenocarcinoma 35 patients, squamous cell carcinoma 32 patients, and small cell carcinoma 42 patients) and 30 patients in the control group. The changes in the content of lung cancer patients before and after chemotherapy were compared. The results showed that the serum levels of CEA, SF, and β2-MG in the lung cancer group were significantly higher than those in the control group (P<0.01), and the positive rates of single test were 56.9%, 72.5%, and 47.7%, respectively. The positive rate of joint detection of CEA, SF, and β2-MG was 91.7%. The content of β2-MG in patients with lung cancer after chemotherapy was not significantly lower than that before chemotherapy (P>0.05), but CEA and SF were significantly decreased (P<0.01). This shows that the joint detection of the above three indicators has important clinical value for the diagnosis and treatment of lung cancer.